The insulin-like growth factor II mRNA-binding protein 1 (IGF2BP1/IMP1) inhibitor BTYNB destabilizes c-MYC mRNA via disrupting IMP1 binding to c-MYC mRNA, thereby repressing ovarian cancer cell proliferation [79]. Here, MYC is linked to ovarian carcinoma.